1. Home
  2. FOR vs DBVT Comparison

FOR vs DBVT Comparison

Compare FOR & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Forestar Group Inc

FOR

Forestar Group Inc

HOLD

Current Price

$30.31

Market Cap

1.2B

Sector

Finance

ML Signal

HOLD

DBVT

DBV Technologies S.A.

HOLD

Current Price

$20.90

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FOR
DBVT
Founded
2005
2002
Country
United States
France
Employees
N/A
N/A
Industry
Real Estate
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.1B
IPO Year
2007
N/A

Fundamental Metrics

Financial Performance
Metric
FOR
DBVT
Price
$30.31
$20.90
Analyst Decision
Strong Buy
Buy
Analyst Count
4
7
Target Price
$31.75
$31.75
AVG Volume (30 Days)
197.6K
477.4K
Earning Date
01-20-2026
10-28-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
3.27
N/A
Revenue
$1,685,000,000.00
$5,502,000.00
Revenue This Year
$0.52
$1,768.71
Revenue Next Year
$7.72
$1,028.88
P/E Ratio
$9.27
N/A
Revenue Growth
15.89
N/A
52 Week Low
$18.00
$3.82
52 Week High
$30.74
$26.19

Technical Indicators

Market Signals
Indicator
FOR
DBVT
Relative Strength Index (RSI) 71.28 48.55
Support Level $29.13 $20.25
Resistance Level $29.87 $24.65
Average True Range (ATR) 0.95 1.54
MACD 0.32 -0.30
Stochastic Oscillator 93.22 13.79

Price Performance

Historical Comparison
FOR
DBVT

About FOR Forestar Group Inc

Forestar Group Inc is a residential lot development company engaged in land acquisition and development for the sale of finished single-family residential lots to local, regional, and national homebuilders. The company operates through a single real estate segment, which acquires land, installs infrastructure for residential communities, and generates all revenue from lot sales. Its communities mainly support entry-level, first-time move-up, and active-adult homes, with certain communities also marketed to build-to-rent operators. the company generally invests in entitled, short-duration projects that can be developed in phases to align lot production with market demand and support efficient capital deployment.

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Share on Social Networks: